Format

Send to

Choose Destination
Cancer Invest. 2015;33(8):331-9. doi: 10.3109/07357907.2015.1047506. Epub 2015 Jun 12.

Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.

Wright JD1,2,3, Tergas AI1,2,3,4, Ananth CV1,4, Burke WM1,2,3, Hou JY1,2,3, Chen L1, Neugut AI2,3,4,5, Richards CA4, Hershman DL2,3,4,5.

Author information

1
a Department of Obstetrics and Gynecology , Columbia University , New York , USA.
2
b Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons , Columbia University , New York , USA.
3
c New York Presbyterian Hospital , New York , USA.
4
d Department of Epidemiology, Mailman School of Public Health , Columbia University , New York , USA .
5
e Department of Medicine, College of Physicians and Surgeons , Columbia University , New York , USA.

Abstract

Using a nationwide database, 4,874 patients with hypercalcemia of malignancy were identified. The in-hospital mortality rate was 6.8%. Overall, 1,971 (40.4%) patients received pamidronate and 1,399 (28.7%) received zoledronic acid during hospitalization. Calcitonin was utilized in 1,337 (27.4%) patients while glucocorticoids were administered to 1,311 (26.9%). Use of contraindicated medications was noted in 136 (2.8%) patients who received thiazide diuretics and 12 (0.2%) who received lithium. Tumor site, presence of bone metastases, and severity of illness were predictors of treatment. There was no association between treatment with bisphosphonates, calcitonin, or glucocorticoids and morbidity or mortality.

KEYWORDS:

Calcium; Hypercalcemia; Malignancy

PMID:
26068056
PMCID:
PMC4666677
DOI:
10.3109/07357907.2015.1047506
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center